CSN3 Inhibitors
COP9 signalosome subunit 3 (CSN3) plays a critical role in the COP9 signalosome complex, a key regulator of the ubiquitin-proteasome system and involved in controlling various cellular processes including cell cycle, signal transduction, and protein degradation. CSN3's function is integral to the dynamic regulation of ubiquitin conjugation and deconjugation, affecting the stability and activity of numerous proteins within the cell. By regulating the ubiquitination status of target proteins, CSN3 influences cellular signaling pathways, cell cycle progression, and the response to cellular stress, underscoring its importance in maintaining cellular homeostasis and responding to environmental cues.
The inhibition of CSN3, whether directly or indirectly, can significantly impact cellular function by altering the normal activity of the COP9 signalosome. Indirect inhibitors of CSN3, such as those listed, typically exert their effects by modulating related pathways or processes that CSN3 is involved in, rather than binding to CSN3 directly. These inhibitors can disrupt the regulatory functions of the COP9 signalosome by affecting proteasome activity, altering signal transduction pathways, or influencing the cell cycle and protein degradation mechanisms. Such inhibition can lead to the accumulation of ubiquitinated proteins, altered cellular signaling, and impaired cellular responses to stress. Understanding the mechanisms through which these chemicals inhibit CSN3 and the COP9 signalosome provides insight into the complex regulatory networks that govern cellular physiology and highlights the potential for targeting these pathways in research into cellular regulation and homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. This leads to an accumulation of proteins and indirectly inhibits CSN3 by disrupting the normal function of the COP9 signalosome in protein degradation regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib specifically inhibits the 26S proteasome, leading to an increase in ubiquitinated protein levels. This indirect inhibition of CSN3 occurs through the disruption of proteasomal degradation pathways, affecting the COP9 signalosome's regulatory functions. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A disrupts proteasomal function and induces oxidative stress, indirectly inhibiting CSN3 by affecting its role in the COP9 signalosome, which is critical for maintaining protein homeostasis and regulating stress responses. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that blocks the degradation of ubiquitin-conjugated proteins. Indirect inhibition of CSN3 is achieved by disrupting the normal processing of proteins regulated by the COP9 signalosome. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol induces heat shock proteins and inhibits NF-κB signaling, leading to proteasome inhibition. This indirectly inhibits CSN3 by affecting the COP9 signalosome's role in protein quality control and degradation pathways. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that blocks the degradation of ubiquitinated proteins, indirectly inhibiting CSN3 by disrupting its function in the COP9 signalosome, which is essential for the regulation of protein turnover. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases involved in cell proliferation and angiogenesis. Indirectly, it inhibits CSN3 by affecting cellular signaling pathways that influence the COP9 signalosome's regulatory activities in cell cycle control and signal transduction. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Tozasertib (VX-680) inhibits Aurora kinases, affecting cell cycle progression and mitotic spindle assembly. This indirectly inhibits CSN3 by disrupting cellular processes regulated by the COP9 signalosome, including cell cycle checkpoints and signal transduction. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual inhibitor of PI3K and mTOR pathways, leading to altered cellular growth signals. Indirect inhibition of CSN3 occurs through changes in signaling pathways that the COP9 signalosome participates in regulating protein stability and signal transduction. | ||||||